Le Lézard
Classified in: Health, Science and technology
Subject: MISCELLANEOUS

Avivagen Announces Approval from TSX Venture Exchange for Extension of Warrants


THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

OTTAWA, March 12, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) ("Avivagen" or the "Company"), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, announces that it has received approval by the TSX Venture Exchange to extend the expiry date of outstanding warrants exercisable to purchase 1,163,738 common shares at $1.00 per share. Such warrants were issued by Avivagen on December 16, 2014 by way of a private placement and previously had an expiry date of December 16, 2017, which was later extended to June 30, 2018.  The new expiry date is October 1, 2018. The Company has also received approval to extend the expiry date of a second tranche of outstanding warrants exercisable to purchase 2,774,991 common shares at $0.90 per share. These warrants were issued by Avivagen on June 1, 2016 by way of a private placement and previously had an expiry date of June 1, 2018. The new expiry date is October 1, 2018.  All other terms and conditions of the warrants remain unchanged.  The Company's intention to seek extension of these warrants was previously announced on February 13, 2018.

About Avivagen
Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About OxC-betatm Technology and OxC-betatm Livestock
Avivagen's OxC-betatm technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-betatm Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-betatm Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.

Avivagen's OxC-betatm Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-betatm Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Vivamunetm Health Chews (Vivamune)
Vivamune is an all-in-one chew that can dramatically simplify a pet's supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient: OxC-betatm compound, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Statements about the potential for Avivagen Inc.'s products to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward- looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations.. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: [email protected]

Kym Anthony
Chairman & Interim CEO
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright © 2018 Avivagen Inc. OxC-betatm is a trademark of Avivagen Inc.


These press releases may also interest you

at 08:40
The "Global Cell Counting Market: Analysis By Product, By Application, By End-User, By Region Size, Trends and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global cell counting market was valued at US$9.98...

at 08:39
Learning Ally, a national nonprofit working with U.S. K12 schools to strengthen reading outcomes, has announced the dates of its ninth Spotlight on Dyslexia virtual conference as June 5th and 6th, 2024. Spotlight on Dyslexia has become one of the...

at 08:35
SOCOTEC USA, a leading provider of TIC (Testing, Inspection, and Certification), consulting, and advisory services with a strategic focus on buildings and infrastructure, announces its collaboration with Bisnow to discuss the critical importance of...

at 08:32
XCMG Machinery (SHE:000425, "XCMG") is proud to announce its recent triumph at the 2024 German Design Awards, where it has been awarded the Excellent Communications Design in Integrated Campaigns and Advertising for its innovative "Cultural Gift"...

at 08:32
As the House's new Task Force on Artificial Intelligence (AI) considers how government should address AI issues, such as deepfakes in the election and bias in algorithms, a new survey conducted by the Program for Public Consultation at the University...

at 08:15
Blue Yonder, a leader in digital supply chain transformations, continues its forward momentum to revolutionize the supply chain and has today announced the signing of an agreement to acquire One Network Enterprises (One Network) for approximately...



News published on and distributed by: